



 github.com/nicksun1

US/Canada Dual Citizen


 [linkedin.com/in/nicholas-sun-ln](https://www.linkedin.com/in/nicholas-sun-ln)

– Nicholas Sun –

nicksun1.github.io

Updated 05/2021 

ns2874@columbia.edu 

(573) 639-2388 

Summary

- Profile** · Statistician and data scientist with extensive experience performing analysis on massive, complex datasets. Interested in development of interpretable and robust tools backed by superior quantitative operating characteristics.
- Areas of Expertise** · Statistical methodology development, large-scale simulation studies, predictive modeling, development of visualization tools. Clinical trials and biomarker studies.
- Frequently used** · R, Python, SAS, Spotfire, SQL.

Education

M.S. Biostatistics , Columbia University Mailman School of Public Health	<i>New York, NY</i>	August 2016-2018
B.S. Mechanical Engineering , Columbia University	<i>New York, NY</i>	August 2012-2016

Professional Experience

Eli Lilly and Company	July 2018-Present
Senior Statistician , Lilly Research Laboratories	<i>Indianapolis, IN</i>

- Lead team to create cross-therapeutic automated visualization tools for adverse events reporting. Utilization increases reliability and decreases phase I dose-escalation review timeline five-fold. Recipient of Lilly Innovator Award 2020.
- Propose novel biomarker prediction models to analyze data from phase I trials. Methodology adopted by various groups working across multiple drug compounds after determination of positive value.
- Develop multiple drug dose-response models that inform stop-and-go strategies for dose-finding trials. Models implemented in ongoing trials. Rigorous simulation study and methodology presented in internal technical report
- Manage production, maintenance, and review of evidence packages submitted to FDA for drug approval.
- Create versatile R functions for creation of highly informative dual y-axis graphs, reflecting new closed loop insulin pump patient data over time. Used by pharmacology team for quick assessment of pump efficacy.
- Build and assess data-driven risk matrix of COVID-19 effect on trial endpoints to inform company-wide decision making process on continuation, viability and pivot direction of all new and on-going clinical trials.
- Head original Lilly initiative for handling and dissemination of confidential study data for public use. Introduce new pipeline for production of company-wide de-identified datasets.
- Contribute to Eli Lilly publications in various academic journals.

National Institute of Health	May-August 2017
Statistician , Biostatistics Branch	<i>Bethesda, MD</i>

- Developed new composite test for performing inference on difference in means with zero-inflated data.
- Authored report recommending new nutritional guidelines based on reanalysis of childhood nutrition dataset.

Software

- [PowerCompareZero](#) R package that includes various functions to compare, test, and run new inference procedures or analysis of semi-continuous data.
- [InsulinSensitivity](#) R and SAS project evaluating best use case for common measure of insulin sensitivity accounting for available information and efficiency and depth of desired conclusion.

Skills and Interests

- Language Proficiency: Mandarin-Full Professional; Spanish-Intermediate
- Community Involvement: Lilly service volunteer Boy Scouts of America (Crossroads of America Council).
- Interests: snowboarding, hiking, ultimate frisbee, fantasy football, online gaming.